Screener
Bausch + Lomb BLCO Surgical — R&D
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Bausch + Lomb in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.
The source filing: Bausch + Lomb’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 4:17 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001860742-26-000088
| (in millions) | Vision Care / Three Months Ended June 30, 2026 | Vision Care / Three Months Ended June 30, 2025 | Pharmaceuticals / Three Months Ended June 30, 2026 | Pharmaceuticals / Three Months Ended June 30, 2025 | Surgical / Three Months Ended June 30, 2026 | Surgical / Three Months Ended June 30, 2025 | Total / Three Months Ended June 30, 2026 | Total / Three Months Ended June 30, 2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of goods sold (excluding amortization and impairments of intangible assets) | 291 | 290 | 89 | 104 | 147 | 129 | ||
| Cost of other revenues | — | — | — | 2 | — | — | ||
| Selling, general and administrative | 247 | 243 | 149 | 154 | 80 | 73 | ||
| Research and development | 17 | 11 | 27 | 12 | 12 | 12 | ||
| Segment Profit | $229 | $209 | $89 | $37 | $17 | $2 | 335 | 248 |
| Corporate | (170) | (170) | ||||||
| Amortization of intangible assets | (57) | (67) | ||||||
| Other expense, net | (25) | (22) |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Bausch + Lomb's surgical — R&D?
- Bausch + Lomb (BLCO) reported surgical — R&D of $12M in Q2 2026.
- How has Bausch + Lomb's surgical — R&D changed year-over-year?
- Bausch + Lomb's surgical — R&D decreased by 0.0% year-over-year, from $12M to $12M.
- What is the long-term trend for Bausch + Lomb's surgical — R&D?
- Over 3 years (2022 to 2025), Bausch + Lomb's surgical — R&D has grown at a 4.2% compound annual growth rate (CAGR), from $38M to $43M.
- What does surgical — R&D mean?
- Represents the investment in scientific research and product development aimed at creating new surgical technologies or improving existing ophthalmic equipment. This is a critical indicator of the segment's commitment to long-term innovation and future product pipeline viability. High levels of investment are typically required to maintain a competitive edge in the surgical market.
Ask your AI about Bausch + Lomb's surgical — r&d.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude